Wednesday’s Midday Movers: TCP International (TCPI), Enteromedics Inc. (ETRM), RXi Pharmaceuticals Corp (RXII), Mast Therapeutics (MSTX), SeaDrill LTD (SDRL)

By Carrie Williams

So far Wednesday, November 23, NASDAQ is down -0.72% and the S&P is up 0.36%. Here are this morning’s most active stocks: TCP International (NYSE:TCPI), Enteromedics Inc. (NASDAQ:ETRM), RXi Pharmaceuticals Corp (NASDAQ:RXII), Mast Therapeutics (NYSE:MSTX) and SeaDrill LTD (NYSE:SDRL).

TCP International is up 26% in midday trading to $1.26. Shares opened today at $1.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00. In the last 30 days, insiders have sold $32.19K worth of TCPI shares. Over the last 3 months, the insider sentiment on TCP International has been neutral based on 13 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Enteromedics Inc. is down -23.39% in midday trading to $0.08. Shares opened today at $0.10. The company has a 52-week low of $0.04 and a 52-week high of $2.85. Over the last 3 months, the insider sentiment on Enteromedics Inc. has been positive based on 4 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.

RXi Pharmaceuticals Corp is down -15.23% in midday trading to $1.81. Shares opened today at $2.14. The company has a 52-week low of $0.94 and a 52-week high of $4.35.

Mast Therapeutics is down -12.5% in midday trading to $0.09. Shares opened today at $0.10. The company has a 52-week low of $0.07 and a 52-week high of $0.71.

SeaDrill LTD is up 11.39% in midday trading to $2.64. Shares opened today at $2.37. The company has a 52-week low of $1.57 and a 52-week high of $7.49. On the Street’s front, the average 12-month analyst price target for the stock is $7.50, marking a 216.46% potential upside from current levels. In a report issued on September 23, Credit Suisse analyst Gregory Lewis reiterated a Sell rating on SDRL, with a price target of $1, which represents a potential downside of 58% from where the stock is currently trading. Separately, on August 30, Morgan Stanley’s Ole Slorer reiterated a Hold rating on the stock and has a price target of $7.50.